Kellogg
Dr. Anne Kellogg has developed a monoclonal antibody that could play a vital role in treating the most common form of ovarian cancer, breast cancer and other cancers. She is working with two major drug firms, ImmunoGen Inc. and sanofi-aventis, that have expertise in formulating antibodies into cancer therapies and taking them to clinical trials in humans.
Kellogg, an associate professor of pathology and laboratory medicine at the Brody School of Medicine at ECU, created the antibody, called DS-6, that attaches to cancer cells in her laboratory at ECU. DS-6 will serve as a delivery vehicle for a highly potent cell-killing agent developed by ImmunoGen specifically for delivery to cancer cells by antibodies. The antibody latches on to tumor cells and enables the whole compound – the antibody and the attached cell-killing agent – to enter the cancer cell. Once inside, the cell-killing agent becomes activated and kills the tumor cell as it divides.
